HK1212340A1 - 用於治療過度增殖性障礙的取代的吲唑-吡咯並嘧啶 - Google Patents

用於治療過度增殖性障礙的取代的吲唑-吡咯並嘧啶

Info

Publication number
HK1212340A1
HK1212340A1 HK16100233.9A HK16100233A HK1212340A1 HK 1212340 A1 HK1212340 A1 HK 1212340A1 HK 16100233 A HK16100233 A HK 16100233A HK 1212340 A1 HK1212340 A1 HK 1212340A1
Authority
HK
Hong Kong
Prior art keywords
hyperfoliferative
disorders
treatment
substituted indazol
pyrrolopyrimidines
Prior art date
Application number
HK16100233.9A
Other languages
English (en)
Inventor
Lars Wortmann
Ulrich Klar
Georg Kettschau
Florian Phler
Philip Lienau
Kirstin Petersen
Andrea Hgebarth
Detlev Slzle
Keith Graham
Anja Richter
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of HK1212340A1 publication Critical patent/HK1212340A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16100233.9A 2012-09-26 2016-01-11 用於治療過度增殖性障礙的取代的吲唑-吡咯並嘧啶 HK1212340A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12186034 2012-09-26
EP13155246 2013-02-14
PCT/EP2013/069779 WO2014048894A1 (en) 2012-09-26 2013-09-24 Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders

Publications (1)

Publication Number Publication Date
HK1212340A1 true HK1212340A1 (zh) 2016-06-10

Family

ID=49230781

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100233.9A HK1212340A1 (zh) 2012-09-26 2016-01-11 用於治療過度增殖性障礙的取代的吲唑-吡咯並嘧啶

Country Status (7)

Country Link
US (1) US20150218173A1 (zh)
EP (1) EP2900670A1 (zh)
JP (1) JP2015531361A (zh)
CN (1) CN104781260A (zh)
CA (1) CA2885787A1 (zh)
HK (1) HK1212340A1 (zh)
WO (1) WO2014048894A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013174744A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Thienopyrimidines
CN104470931B (zh) 2012-05-21 2016-10-26 拜耳医药股份有限公司 取代的苯并噻吩并嘧啶
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
JP2016512491A (ja) 2013-03-06 2016-04-28 バイエル・ファルマ・アクティエンゲゼルシャフト 置換チアゾロピリミジン類
KR20180004740A (ko) 2015-04-20 2018-01-12 이펙터 테라퓨틱스, 인크. 암 및 감염 치료에 사용하기 위한 면역 체크포인트 조절 인자의 억제제
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US20170191136A1 (en) 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
US11020398B2 (en) 2016-08-24 2021-06-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ES2203642T3 (es) 1995-06-07 2004-04-16 Pfizer Inc. Derivados de pirimidina heterociclicos con anillos condensados.
EP0946554A1 (en) 1996-11-27 1999-10-06 Pfizer Inc. Fused bicyclic pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US7253166B2 (en) * 2003-04-22 2007-08-07 Irm Llc 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells
AR050365A1 (es) 2004-08-02 2006-10-18 Osi Pharm Inc Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos.
CN101052629A (zh) * 2004-08-02 2007-10-10 Osi制药公司 芳基－氨基取代的吡咯并嘧啶多激酶抑制化合物
EP2001480A4 (en) 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
CA2768821A1 (en) * 2009-07-28 2011-02-03 Ube Industries, Ltd. Pyrrolo[2,3-d]pyrimidine derivative
MX2012005827A (es) * 2009-11-18 2012-06-19 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
CA2785716A1 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds

Also Published As

Publication number Publication date
EP2900670A1 (en) 2015-08-05
CA2885787A1 (en) 2014-04-03
US20150218173A1 (en) 2015-08-06
WO2014048894A1 (en) 2014-04-03
CN104781260A (zh) 2015-07-15
JP2015531361A (ja) 2015-11-02

Similar Documents

Publication Publication Date Title
IL283943A (en) Use of pyrazolopyrimidine derivatives for the treatment of p13k associated disorders
HK1222552A1 (zh) 索布替羅用於治療髓鞘形成疾病
PL3811943T3 (pl) Związek do stosowania w leczeniu zaburzeń oczu
HRP20180659T1 (hr) Disperzija amorfne krutine, namijenjena upotrebi u liječenju raka na mozgu
HK1213542A1 (zh) 用於治療過度增殖性疾病的取代的吲唑-吡咯並嘧啶
HK1212340A1 (zh) 用於治療過度增殖性障礙的取代的吲唑-吡咯並嘧啶
HK1207860A1 (zh) 用於治療糖尿病及其相關病症的 -苯基- -雜環基-四氫- -吡喃- -胺化合物
IL235127A (en) Hpn-100 for use in the treatment of nitrogen-related diseases
SI2872176T1 (sl) Karboranilporfirin za uporabo pri zdravljenju raka
HK1209033A1 (zh) 奧地帕西在治療黏多醣症病中的應用
LT2863932T (lt) Kompozicija, skirta naudoti limfedemos gydymui